RNXT Revenue third quarter 2026 Y/Y Growth Comment
Renovorx Inc achieved in the third quarter 2026, above Company average Revenue surge of 294.81% year on year, to $ 1.07 millions.
Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 65 other companies have achieved higher Revenue growth. While Renovorx Inc ' s Revenue doubling of 294.81% ranks overall at the positon no. 808 in the third quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Renovorx Inc 's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
358.14 %
103.81 %
-36.97 %
(Mar 31 2025)
RNXT's III. Quarter Q/Q Revenue Comment
Renovorx Inc achieved in the III. Quarter 2026 below company average Revenue jump of 17.14% quarter on quarter, to $ 1.07 millions.
Although the III. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the -35.71% growth in the III. Quarter a year ago
Within Major Pharmaceutical Preparations industry 30 other companies have achieved higher Revenue quarter on quarter growth. While Renovorx Inc 's Revenue growth quarter on quarter, overall rank is 196.
Renovorx Inc achieved in the III. Quarter 2026 below company average Revenue jump of 17.14% quarter on quarter, to $ 1.07 millions.
III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -35.71% in the III. Quarter a year ago.
Within Major Pharmaceutical Preparations industry 30 other companies have achieved higher Revenue quarter on quarter growth. While Renovorx Inc 's Revenue growth quarter on quarter, overall rank is 196.
Renovorx Inc 's 12 Months Revenue Growth Year on Year
Renovorx Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 294.81% year on year, to $ 2 millions if the fiscal year would have ended in Jun 30 2026. Renovorx Inc 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Mar 31 2026. And, Renovorx Inc realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry. But from twelve months ended Mar 31 2026 rise was beneth at 32.71 % from $1.49 millions achieved in the period from Mar 31 2026 to Jun 30 2025. Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 0%.
Renovorx Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .
Renovorx Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 294.81% year on year, to $ 2 millions if the fiscal year would have ended in Jun 30 2026. Renovorx Inc 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Mar 31 2026. And, Renovorx Inc realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry. But from twelve months ended Mar 31 2026 rise was beneth at 32.71 % from $1.49 millions achieved in the period from Mar 31 2026 to Jun 30 2025. Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 0%. The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 32.71 % increase from $1.49 millions in the period from Mar 31 2026 to Jun 30 2025.
Renovorx Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .
About Renovorx Inc Revenue Growth Rates (RNXT), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
460.49%